EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · IEX Real-Time Price · USD
8.85
-0.82 (-8.48%)
At close: Jul 18, 2024, 4:00 PM
8.84
-0.01 (-0.11%)
After-hours: Jul 18, 2024, 4:22 PM EDT

Company Description

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.

The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.

Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME).

The company’s pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases.

The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018.

EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals logo
Country United States
Founded 1987
IPO Date Jan 27, 2005
Industry Biotechnology
Sector Healthcare
Employees 121
CEO Dr. Jay S. Duker M.D.

Contact Details

Address:
480 Pleasant Street, Suite B300
Watertown, Massachusetts 02472
United States
Phone 617-926-5000
Website eyepointpharma.com

Stock Details

Ticker Symbol EYPT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001314102
CUSIP Number 30233G209
ISIN Number US30233G2093
Employer ID 26-2774444
SIC Code 3826

Key Executives

Name Position
Dr. Jay S. Duker M.D. President, Chief Executive Officer and Director
Dr. John B. Landis M.S., Ph.D. Interim Head of Research & Development and Director
Michael Pine Chief Business Officer
George O. Elston Executive Vice President and Chief Financial Officer
Michael J. Maciocio Senior Vice President of Manufacturing and Operations
Ron I. Honig Esq. Chief Legal Officer and Company Secretary
Jennifer Leonard Chief People Officer and Senior Vice President of IT
David Scott Jones Senior Vice President and Chief Commercial Officer
Isabelle Lefebvre Chief Regulatory Officer
Dr. Marcia Sellos-Moura Ph.D. Senior Vice President of Program Leadership

Latest SEC Filings

Date Type Title
Jun 26, 2024 8-K Current Report
Jun 21, 2024 8-K Current Report
May 28, 2024 8-K Current Report
May 14, 2024 144 Filing
May 9, 2024 10-Q Quarterly Report
May 8, 2024 8-K Current Report
May 6, 2024 8-K Current Report
May 1, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Apr 30, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Apr 26, 2024 DEF 14A Other definitive proxy statements